- Home
- JRS vs RAPT Comparison
JRS vs RAPT Comparison
Compare JRS & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JRS
- RAPT
- Stock Information
- Founded
- JRS 2001
- RAPT 2015
- Country
- JRS United States
- RAPT United States
- Employees
- JRS N/A
- RAPT N/A
- Industry
- JRS Finance/Investors Services
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- JRS Finance
- RAPT Health Care
- Exchange
- JRS Nasdaq
- RAPT Nasdaq
- Market Cap
- JRS 224.5M
- RAPT 194.2M
- IPO Year
- JRS N/A
- RAPT 2019
- Fundamental
- Price
- JRS $8.02
- RAPT $11.32
- Analyst Decision
- JRS
- RAPT Buy
- Analyst Count
- JRS 0
- RAPT 5
- Target Price
- JRS N/A
- RAPT $33.60
- AVG Volume (30 Days)
- JRS 86.6K
- RAPT 104.8K
- Earning Date
- JRS 01-01-0001
- RAPT 08-07-2025
- Dividend Yield
- JRS 8.87%
- RAPT N/A
- EPS Growth
- JRS N/A
- RAPT N/A
- EPS
- JRS N/A
- RAPT N/A
- Revenue
- JRS N/A
- RAPT N/A
- Revenue This Year
- JRS N/A
- RAPT N/A
- Revenue Next Year
- JRS N/A
- RAPT N/A
- P/E Ratio
- JRS N/A
- RAPT N/A
- Revenue Growth
- JRS N/A
- RAPT N/A
- 52 Week Low
- JRS $5.95
- RAPT $5.67
- 52 Week High
- JRS $8.00
- RAPT $26.56
- Technical
- Relative Strength Index (RSI)
- JRS 66.64
- RAPT 54.68
- Support Level
- JRS $7.77
- RAPT $10.06
- Resistance Level
- JRS $7.87
- RAPT $12.25
- Average True Range (ATR)
- JRS 0.10
- RAPT 1.02
- MACD
- JRS 0.04
- RAPT -0.05
- Stochastic Oscillator
- JRS 87.36
- RAPT 73.29
About JRS Nuveen Real Estate Income Fund of Beneficial Interest
Nuveen Real Estate Income Fund is a diversified closed-end investment company. The Fund invests primarily in income-producing common stocks, preferred stocks, convertible preferred stocks, and debt securities issued by real estate companies.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.